Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

electroCore, Inc. Announces Closing of Initial Public Offering

June 26, 2018 at 9:00 AM EDT

BASKING RIDGE, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced the closing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. The proceeds from this offering, net of underwriting discounts and commissions, are approximately $72,540,000. In addition, electroCore has granted the underwriters a 30‑day option to purchase up to an additional 780,000 shares of common stock at the initial public offering price less discounts and commissions.  All shares of common stock in the offering were sold by electroCore.

electroCore’s common stock began trading on the Nasdaq Global Market on June 22, 2018 under the symbol ECOR.

Evercore ISI, Cantor Fitzgerald & Co. and JMP Securities acted as joint book-running managers for the offering. BTIG, LLC acted as lead manager.

A registration statement related to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective by the SEC the on June 21, 2018. Copies of the registration statement may be accessed through the SEC’s website at www.sec.gov.

The offering was made only by means of a prospectus forming part of the registration statement. Copies of the final prospectus related to the offering may be obtained from: Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by phone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 5th Floor, New York, NY 10022, or by phone at (212) 829-7122, or by email at prospectus@cantor.com; or JMP Securities LLC, 600 Montgomery Street, 11th Floor, San Francisco, California 94111, or by phone at (415) 835-8985, or by email at syndicate@jmpsecurities.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About electroCore
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the acute treatment of migraine and episodic cluster headache.

Contacts

Investors:
Greg Chodaczek or Lynn Lewis
Gilmartin Group
investors@electrocorellc.com
(610) 368-6505

or

Media:
Alexandra Canale 
GCI Health
(617) 921-9353
alexandra.canale@gcihealth.com